Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Chronic Kidney Disease IV: Nursing Management

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Acute Kidney Injury II: Pathophysiology

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Survey of Home Dialysis Competency, Exposure, and Barriers Among Nephrology Fellows in the United States.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026

Same author

Sports Nephrology: From Bench to Bedside.

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

American Board of Internal Medicine Nephrology: Pressing Issues and Insights.

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis.

Rheumatology (Oxford, England)·2025

Same author

Long-Term Effects of Sodium-Glucose Cotransporter Inhibitors on Refractory Hypomagnesemia and Urinary Magnesium Excretion.

Mayo Clinic proceedings·2025

Same author

Impact of Treatment Modalities on Intensive Care Unit Length of Stay for Patients Admitted With Severe Hyponatremia.

The Annals of pharmacotherapy·2025

Search research articles

Related Experiment Video

Updated: Feb 23, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Baclofen Toxicity in Kidney Disease.

Erin Wolf¹, Niraj R Kothari¹, John K Roberts¹

¹Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation

|September 14, 2017

Summary

Baclofen toxicity can occur in patients with kidney disease. Prompt recognition and hemodialysis effectively reversed neurotoxicity and instability in a patient with end-stage kidney disease.

Keywords:

Baclofen creatinine clearance decreased kidney function drug dosing drug toxicity end-stage kidney disease (ESKD)hemodialysis muscle relaxant pharmacokinetics renal clearance

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

Related Experiment Videos

Last Updated: Feb 23, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

Area of Science:

Nephrology
Pharmacology
Neuroscience

Background:

Baclofen, a muscle relaxant, is renally excreted.
Impaired kidney function increases the risk of baclofen toxicity.
Toxicity can manifest as neurotoxicity and hemodynamic instability.

Observation:

A patient with end-stage kidney disease on hemodialysis developed baclofen-induced neurotoxicity and hemodynamic instability.
The patient's symptoms were reversed following prompt recognition and emergent hemodialysis.

Findings:

This case highlights the critical need for careful baclofen dosing in renal impairment.
Pharmacokinetic and pathophysiological mechanisms of baclofen toxicity were examined.
Urgent hemodialysis proved effective in managing severe baclofen toxicity.

Implications:

Reduced baclofen dosage is recommended for moderate kidney dysfunction (eGFR 30-60 mL/min/1.73m²).
Baclofen use should be avoided in severe kidney dysfunction (eGFR <30 mL/min/1.73m²) or renal replacement therapy.
This underscores the importance of tailored drug management in patients with compromised renal function.